April 22, 2014 3:06pm EDT
Download as PDF
MIAMI--(BUSINESS WIRE)--
OPKO Health, Inc. (NYSE: OPK) today announced that it will present data
on its long acting oxyntomodulin (MOD-6030) product on April 25, 2014 at
the 7 th Diabetes Drug Discovery and Development Conference
being held in Cambridge, MA. Company scientists will make an oral
presentation discussing MOD-6030, the company's long-acting GLP-1 and
Glucagon dual agonist with potential for the treatment of type 2
diabetes and obesity. Pre-clinical data shows the drug induced a marked
weight loss and food intake inhibition in both animal models which were
superior compared to those with bi-daily injections of native OXM and to
bi-daily injections of existing marketed drugs.
The 7 th Diabetes Drug Discovery and Development Conference is
being held April 23-25, in Cambridge, MA. For more information, visit: http://www.gtcbio.com/conference/diabetes-drug-discovery-and-development-overview .
ABOUT OPKO HEALTH, INC.
OPKO is a multinational biopharmaceutical and diagnostics company that
seeks to establish industry-leading positions in large, rapidly growing
markets by leveraging its discovery, development and commercialization
expertise and novel and proprietary technologies. For more information,
visit http://www.opko.com.
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), regarding product development efforts and other
non-historical facts about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects, including statements regarding our expectations
about MOD-6030, whether MOD-6030 will induce marked weight loss and food
inhibition or have superior performance compared to other drugs, and
whether we will be able to successfully develop, obtain approval for and
launch sales of MOD-6030. Many factors could cause our actual activities
or results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include those
described in our filings with the Securities and Exchange Commission, as
well as risks inherent in funding, developing and obtaining regulatory
approvals of new, commercially-viable and competitive products and
treatments, including the risks that clinical trials for MOD-6030 may
not be successful or achieve the expected results or effectiveness, and
may not generate data that would support the approval or marketing of
this product for the indications being studied, that others may develop
products which are superior to MOD-6030, and that MOD-6030 may not have
advantages or prove to be superior over presently marketed products. In
addition, forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press release
speak only as of the date the statements were made and we do not
undertake any obligation to update forward-looking statements. We intend
that all forward-looking statements be subject to the safe-harbor
provisions of the PSLRA.
OPKO Health, Inc.
Steven D. Rubin or Adam Logal, 305-575-4100
Source: OPKO Health, Inc.
Released April 22, 2014
email Email Alerts
location_city Company Profile
contact_page Contacts
rss_feed RSS News Feed
account_tree Sitemap
Apply on OPKO Health (Ireland)’s careers page